Current Oncology Reports

, 16:400 | Cite as

Immunotherapeutic Agents in Non-small-cell Lung Cancer Finally Coming to the Front Lines

  • Rossana RuizEmail author
  • Brian Hunis
  • Luis E. Raez
Lung Cancer (T Mekhail, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Lung Cancer


Non-small-cell lung cancer usually carries a dismal prognosis. Novel treatment approaches are clearly warranted. Immunotherapy has emerged as a promising area of research developing agents that manipulate the immune system to induce antitumor responses while avoiding major toxicity. New vaccines and checkpoint inhibitors are currently undergoing investigation in phase II and phase III clinical trials. In advanced non-small-cell lung cancer (NSCLC), belagenpumatucel-L, an allogeneic cell vaccine directed against transforming growth factor β in the tumor microenvironment, knocks down the immune suppression caused by the tumor and has demonstrated a dose- and time-dependent efficacy in some subgroups of patients. L-BLP25 and TG4010 are both antigenic vaccines that target mucin 1, whose encoding proto-oncogene is commonly mutated in solid tumors. The L-BLP25 vaccine achieved a significant improvement in overall survival in the subgroup of patients with stage IIIB NSCLC treated with chemoradiotherapy. TG4010 vaccination resulted in better progression-free survival when added to cisplatin–gemcitabine chemotherapy. These results are being addressed in the currently ongoing phase III TIME trial. In the adjuvant setting, MAGE-A3, an antigen-based vaccine, showed promising results in melanoma-associated antigen A3 positive lung cancer patients who underwent resection in the phase II study; however, no improvement in progression-free survival was observed in the phase III MAGRIT study. CIMAVax is a recombinant human epidermal growth factor (EGF) vaccine that induces anti-EGF antibody production and prevents EGF from binding to its receptor. It has improved overall survival in patients with advanced NSCLC who achieve seroconversion. Ipilimumab, an immune checkpoint inhibitor that targets cytotoxic T-lymphocyte antigen 4, demonstrated improved progression-free survival in advanced NSCLC patients who received the drug after chemotherapy in a phased regimen. Finally, anti-programmed death receptor 1 agents have achieved durable response rates in phase I studies. This review gives an overview of the current data and the most promissory immunotherapeutic agents for NSCLC.


Immunotherapy Non-small-cell lung cancer L-BLP25 Anti-CTLA4 Anti-PD1/PDL1 


Compliance with Ethics Guidelines

Conflict of Interest

Rossana Ruiz and Brian Hunis declare that they have no conflict of interest.

Luis E. Raez has received grants from Merck Serono, GlaxoSmithKline, and Pfizer unrelated to the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Johnson DH, Schiller JH, Bunn PA. Recent clinical advances in lung cancer management. J Clin Oncol. 2014;32(10):973–82.PubMedCrossRefGoogle Scholar
  3. 3.
    Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One. 2007;2(11):e1129.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Belalcazar A, Raez LE, Santos ES. Immunotherapy for nonsmall-cell lung cancer. MEMO. 2012;5(2):90–3.CrossRefGoogle Scholar
  5. 5.
    Perez CA, Santos ES, Raez LE. Active immunotherapy for non-small-cell lung cancer: moving toward a reality. Expert Rev Anticancer Ther. 2011;11(10):1599–605.PubMedCrossRefGoogle Scholar
  6. 6.
    Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012;23 Suppl 8:viii6–9.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Finn OJ. Cancer immunology. N Engl J Med. 2008;358:2704–15.PubMedCrossRefGoogle Scholar
  8. 8.
    Campoli M, Ferrone S, Zea AH, Rodriguez PC, Ochoa AC. Mechanisms of tumor evasion. Cancer Treat Res. 2005;123:61–88.PubMedCrossRefGoogle Scholar
  9. 9.
    Kelly RJ, Giaccone G. Lung cancer vaccines. Cancer J. 2011;17(5):302–8.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Ruffini E, Asioli S, Filosso PL, Lyberis P, Bruna MC, Macrì L, et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg. 2009;87(2):365–71. discussion 371-2.PubMedCrossRefGoogle Scholar
  11. 11.
    Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol. 2010;5(5):585–90.PubMedGoogle Scholar
  12. 12.
    Bierie B, Moses HL. Transforming growth factor beta (TGF-β) and inflammation in cancer. Cytokine Growth Factor Rev. 2010;21(1):49–59.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS. Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer. 1999;86(9):1712–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Malkoski SP, Haeger SM, Cleaver TG, Rodriguez KJ, Li H, Lu SL, et al. Loss of transforming growth factor beta type II receptor increases aggressive tumor behavior and reduces survival in lung adenocarcinoma and squamous cell carcinoma. Clin Cancer Res. 2012;18(8):2173–83.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small cell lung cancer. J Clin Oncol. 2006;24:4721–30.PubMedCrossRefGoogle Scholar
  16. 16.••
    Giaccone G, Bazhenova L, Nemunaitis J, et al. A phase III study of belagenpumatucel-L therapeutic tumor cell vaccine for non-small cell lung cancer. 2013. European Cancer Congressl. Abstract LBA 2. Presented September 28, 2013. This presents the results of an important first phase III trial done with belangenpumatucel-L that showed a beneficial effect in subgroup analysis. Google Scholar
  17. 17.
    Sienel W, Varwerk C, Linder A, et al. Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg. 2004;25(1):131–4.PubMedCrossRefGoogle Scholar
  18. 18.
    Gure AO, Chua R, Williamson B, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small-cell lung cancer. Clin Cancer Res. 2005;11:8055–62.PubMedCrossRefGoogle Scholar
  19. 19.
    Vansteenkiste J, Zielinski M, Linder A, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non small cell lung cancer (NSCLC). J Clin Oncol. 2006;s25:7554.Google Scholar
  20. 20.
    GlaxoSmithKline. GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer. In: [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: Accessed 1 May 2014.
  21. 21.•
    GlaxoSmithKline. Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer. 2014. Available from: Accessed 30 Apr 2014. This is a press release announcing the negative results of the phase III multicenter MAGRIT with the MAGE-A3 vaccine.
  22. 22.
    Raina D, Kosugi M, Ahmad R, et al. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther. 2011;10(5):806–16.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.••
    Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(1):59–68. This presents very important negative results of the phase III trial with the L-BLP25 vaccine but that showed a benefit in the subgroup of patients who underwent chemotherapy and radiotherapy, which is the reason for the ongoing START2 trial.PubMedCrossRefGoogle Scholar
  24. 24.
    Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol. 2005;23(27):6674–81.PubMedCrossRefGoogle Scholar
  25. 25.
    Butts C, Maksymiuk A, Goss G, et al. A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis: B1-01. J Thorac Oncol. 2007;2(8):s332–3.CrossRefGoogle Scholar
  26. 26.
    Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996;88:1210–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Curran WJ, Paulus R, Langer CJ, et al. Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103:1452–60.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non–small-cell lung cancer. J Clin Oncol. 1999;17:2692–9.PubMedGoogle Scholar
  29. 29.
    Gelbard A, Garnett CT, Abrams SI, et al. Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res. 2006;12:1897–905.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.•
    Wu YL, Park K, Soo RA, et al. INSPIRE: a phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer. 2011;11:430. This is an Asian study that is the “sister” of the START study done in the Western world with the L-BLP25 vaccine.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    EMD Serono. Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer (START2). In: [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: Accessed 1 May 2014.
  32. 32.
    Ramlau R, Quoix E, Rolski J, et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J Thorac Oncol. 2008;3(7):735–44.PubMedCrossRefGoogle Scholar
  33. 33.••
    Acres B, Quoix E, Ramlau R, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol. 2011;12(12):1125–33. This presents promissory results of the randomized phase II study with TG4010 that showed a beneficial effect in some subset analyses.PubMedCrossRefGoogle Scholar
  34. 34.
    Transgene. Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer (TIME). In: [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from Accessed 2 May 2014.
  35. 35.
    Rodriguez G, Airama A, Viña L, et al. Manufacturing process development for an epidermal growth factor-based cancer vaccine. Int Biopharm. 2008;21(10):36–42.Google Scholar
  36. 36.
    González G, Crombet T, Catalá M, et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol. 1998;9(4):431–5.PubMedCrossRefGoogle Scholar
  37. 37.
    González G, Crombet T, Neninger E, Viada C, Lage A. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. Hum Vaccin. 2007;3(1):8–13.PubMedCrossRefGoogle Scholar
  38. 38.
    Neninger Vinageras E, de la Torre A, Osorio Rodríguez M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol. 2008;26(9):1452–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–3.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100:8372–7.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.••
    Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30(17):2046–54. This is a very important trial, the first phase III trial with ipilimumab in lung cancer. The trial met its primary objective only in the phased ipilimumab arm.PubMedCrossRefGoogle Scholar
  42. 42.
    Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res. 2009;15:7412–20.PubMedCrossRefGoogle Scholar
  43. 43.
    Bristol-Myers Squibb. Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin. In: [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Available from: Accessed 9 May 2014.
  44. 44.
    Topalian SL, Hodi S, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Brahmer JR, Horn L, Antonia S, et al. Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC). J Clin Oncol. 2012;30(15 Suppl):7509.Google Scholar
  46. 46.••
    Brahmer JR, Horn L, Scott A, et al. Survival and long-term follow-up of the phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC). J Cln Oncol. 2013;31(1 Suppl):8030. This is a very important publication with the promissory results of the phase I trial of the checkpoint inhibitor nivolumab in NSCLC.Google Scholar
  47. 47.••
    Garon EB, Balmanoukian A, Hamid O, Hui R, Gandhi L, Leighl N, et al. Abstract A20:MK-3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): preliminary safety and clinical activity. Clin Cancer Res. 2014;20(2 Suppl):A20. This is a very important publication with the promissory results of the phase I trial of MK-3475 in NSCLC.CrossRefGoogle Scholar
  48. 48.••
    Soria JC, Cruz C, Bahleda R, Delord JP, Horn L, Herbst RS, Spigel D, Mokatrin A, Fine G, Gettinger S. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). European Cancer Conference abstract 3408. 2013. This is a very important publication with the promissory results of the phase I trial of MPDL3280A. Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Departamento de Medicina OncológicaInstituto Nacional de Enfermedades NeoplásicasLimaPeru
  2. 2.Thoracic Oncology Program, Memorial Cancer Institute, Memorial Health Care System, Herbert Wertheim College of MedicineFlorida International UniversityPembroke PinesUSA
  3. 3.Memorial Cancer Institute, Memorial Health Care System, Herbert Wertheim College of MedicineFlorida International UniversityPembroke PinesUSA

Personalised recommendations